title: Technetium-99m (⁹⁹mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?
abstract: We report two cases of malignant external otitis (MEO) evaluated with Technetium-99m((99m)Tc)-labelled sulesomab. Two patients affected by MEO are presented, together with a literature review. Both patients were studied with clinical examination, ear discharge culture, radiological imaging, blood exams, (99m)Tc Sulesomab, and treated with antibiotic therapy. (99m)Tc-Sulesomab would appear to be an useful tool for diagnosis and follow-up of MEO, highlighting the site and extension of the inflammatory process, and evaluating course and treatment efficacy. (99m)Tc-Sulesomab shows promise as a rapid, effective and safe imaging agent for treatment response evaluation and follow-up of patients with MEO. Further studies are warranted to validate the inclusion of (99m)Tc-Sulesomab scan in the imaging follow-up of patients with MEO.
authors.affiliation: Department of Otorhinolaryngology, University of Messina, Messina, Italy, ent.messina@hotmail.it.
authors.forename: Francesco
authors.initials: F
authors.lastname: Galletti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cammaroto
authors.forename: Bruno
authors.initials: B
authors.lastname: Galletti
authors.forename: Natale
authors.initials: N
authors.lastname: Quartuccio
authors.forename: Francesca
authors.initials: F
authors.lastname: Di Mauro
authors.forename: Sergio
authors.initials: S
authors.lastname: Baldari
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D060085:Coinfection / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D048909:Diabetes Complications / Q000382:microbiology*; D003937:Diagnosis, Differential; D019468:Disease Management; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D008297:Male; D010032:Otitis Externa / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D011513:Proteus mirabilis / Q000302:isolation & purification; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D011877:Radionuclide Imaging / Q000379:methods*; D019275:Radiopharmaceuticals / Q000494:pharmacology; D013212:Staphylococcus epidermidis / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D019275:Radiopharmaceuticals; C101172:Sulesomab